46results about How to "Thrombolytic effect is good" patented technology

The invention discloses a selenium-rich natto product, which comprises the following components in parts by weight: 35-50 parts of selenium-rich natto powder, 10-16 parts of phytosterol powder and 10-15 parts of green tea extract powder. The selenium-rich natto powder contains selenium natto kinase with high activity and long lasting time, and organic selenium, thus having an excellent antioxidation effect; phytosterol contained in the phytosterol powder has the effects of inhibiting cholesterol absorption of a human body, promoting katabolism of cholesterol, inhibiting biochemical synthesis of the cholesterol and the like; and catechinic acid contained in the green tea extract powder has the effects of inhibiting blood pressure and blood sugar, reducing cholesterol and low density lipoprotein in blood and increasing the content of high density lipoprotein. According to the selenium-rich natto product, the selenium-rich natto powder, the phytosterol powder and the green tea extract powder are combined in scientific proportion to take effect together in three aspects of inhibiting thrombus formation, improving thrombus dissolution and enhancing the toughness of blood vessels, and therefore, the selenium-rich natto product is capable of effectively preventing cardiovascular and cerebrovascular diseases.

The invention discloses a thrombolysis tube, relating to the medical equipment technology field. The thrombolysis tube comprises a tube main body and a connector connected to the rear end of the tube body; the tube main body comprises an outer tube and an inner tube; the outer tube sleeves the inner tube; a drug filling cavity is a gap between the outer tube and the inner tube; a tube cavity of the inner tube is a drainage cavity; the drug filling cavity is isolated from the drainage cavity; the connector comprises a first port and a second port; the first port is communicated with the drainage cavity; the second port is communicated with the drug filling cavity; an opening is formed in the front end of the drainage cavity; the front end of the outer tube is welded together with the outer circumference surface of the inner tube so as to make the front end of the drug filling cavity sealed; a drainage hole which is used for guiding blood to the drainage cavity and a plurality of drug outlet holes communicating with the drug filling cavity are formed on the tube wall of the outer tube; the drainage hole is arranged behind the drug outlet holes; the drainage hole is communicated with the drainage cavity through the flow guiding tube; the flow guiding tube passes through the drug filling cavity and the two ends of the flow guiding tube are correspondingly connected to the drainage hole and the drainage cavity. The thrombolysis tube makes sure blood circulation is smooth and guarantees a good thrombolysis effect.

The invention discloses a drug-loaded magnetic microbubble, and a preparation method and application thereof. A drug-loaded nanometer particle packaged magnetic microbubble is formed by loading drug into mesoporous silica particles and self-assembling drug-loaded silicon dioxide nanometer particles and magnetic nanometer particles in a gas-liquid interface formed through a homogenizer in ice-bathenvironment. The drug-loaded magnetic microbubble is applied to drugs for treating phlebothrombosis, not only can protect thrombolytic drug, but also has rapid response, magnetic targeted enrichment and drug ultrasonic release, can increase the thrombolysis speed, and can solve low drug efficiency, toxic and side effect and bleeding complications in clinic thrombus treatment.

Production of natto kinase and its use are disclosed. The process is carried out by taking sugar, soy-bean and starch as raw materials, using hay bacillus high-yield thrombolytics kinase strain, deep liquid fermenting, adjusting metabolism by complex system, membrane separating, and freeze-drying to obtain the final product. It belongs to serine proteinase and can be used to melt thrombus, inhibit platelet coagulation, prevent hypertension and arteriosclerosis, adjust blood fat and keep blood flow unblocked, and it can be developed as infusion granule, tablet, capsule and oral liquid.

The invention relates to the technical field of medical apparatuses. The invention discloses a built-in medical ultrasonic thrombolytic therapy apparatus, which comprises an infusion device, an ultrasonic loading module and an ultrasonic indwelling wave-guide tube. A front cover plate and an amplitude-change pole of an ultrasonic transducer in the ultrasonic loading module are made from a TC4 titanium alloy material, and through holes, which are [phi]1mm in diameter, are kept in the middles of the front cover plate and the amplitude-change pole. The ultrasonic indwelling wave-guide tube entersinto a blood vessel from the upstream side of the blood vessel that thrombus occurs along the direction of a blood flow. A plurality of small holes are excavated in two sides of the part, which enters the blood vessel, of the ultrasonic indwelling wave-guide tube, so that ultrasonic wave is directly emitted into the blood vessel having the thrombus, and then under the assistance of thrombolytic agent, the thrombus can be ablated. Based upon experimental verification, the therapy apparatus, on treating thrombotic diseases, is non-invasive, simple and convenient to operate and suitable for reuse. Ultrasonic energy merely plays a local role in vivo, and an ultrasonic action and medicines directly reach focuses, so that a good thrombolysis effect is achieved; and meanwhile, the therapy apparatus has the huge advantages of being low in injury on surrounding tissues, safe and free from side effects and adverse reactions, and the like.

The invention provides a natto fermentation composition for relieving arteriosclerosis as well as a preparation method and application of the natto fermentation composition, and belongs to the technical field of bioengineering. The natto fermentation composition for relieving arteriosclerosis is prepared from the following raw materials in parts by weight: 70-120 parts of natto fermentation extract, 1-2 parts of ginsenoside Re, 7-12 parts of notoginsenoside S and 10-20 parts of cyclocarya paliurus flavone. The preparation method disclosed by the invention is simple, the raw materials are wide in source, and the prepared composition has good effects of reducing blood fat and dissolving thrombus; in particular, the compound has good inhibition and treatment effects on atherosclerosis, is safe and free of side effects, can be used as a raw material of dietary therapy products, health-care foods and medicines, and has a wide application prospect.

The invention discloses a thrombolytic liquid preparation capable of avoiding fibrinogen degradation. The thrombolytic liquid preparation is characterized in that the thrombolytic liquid preparation is prepared from FGFCI powder, a cosolvent and normal saline, wherein the concentration of the FGFCI in the thrombolytic liquid preparation is 1-5 mg / mL. The thrombolytic liquid preparation provided by the invention has advantages, in a concentration range in which thromboclasis can be performed, comprising good repeatability and quality stabilization. In addition, in-vitro Caco-2 experiments show that a proper administration route for the FGFCI is intravenous injection which fully meets the needs of clinical medication, and reduction of bleeding risk and achievement of good thrombolytic effects.

The invention discloses a preparation method of targeted thrombolytic microcapsules, which belongs to the technical field of biological materials, the method and comprises the following steps: 1) adding soluble microspheres serving as inner cores into a dopamine solution to prepare polydopamine modified microspheres; 2) further reacting the polydopamine modified microsphere with platelet ligand protein to obtain the active biological protein modified microspheres; and 3) dissolving and etching the microsphere core of the prepared microsphere through a proper mild solvent to obtain the hollow microcapsule structure capable of loading a drug, and then loading thrombolytic drugs to obtain the thrombolytic microspheres with the targeting function. Through surface modification and solvent etching technologies, the drug-loaded hollow microcapsule with good biocompatibility is prepared, and meanwhile, the preparation method and process are simple, the surface structure is stable, and excellent thrombolysis performance, blood compatibility and practicability are achieved.

The invention discloses a thrombolysis device promoting absorption of medicine by using ultrasonic waves, and belongs to the technical field of medical instruments. The thrombolysis device promoting absorption of medicine by using ultrasonic waves comprises an operating handle, a medicine release catheter and an ultrasonic guide wire, wherein the operating handle is fixedly connected with the medicine release catheter through a Ruhr joint; and the operating handle consists of a casing, an ultrasonic generator, an ultrasonic transducer, a battery, an ultrasonic switch and an ultrasonic adjusting knob. The thrombolysis device promoting absorption of medicine by using ultrasonic waves performs continuous ultrasonic cavitation treatment on the thrombolysis medicine at a thrombus part, and greatly promotes penetration and dissolution of thrombus by the thrombolysis medicine; the ultrasonic guide wire is located in a medicine release catheter, and does not make contact with blood vessel walls or damage blood vessel walls and surrounding tissue. When used for clearing thrombus, the thrombolysis device promoting absorption of medicine by using ultrasonic waves has the advantages of good thrombolysis effects, short treatment time, simple operation, safety, reliability and the like.

This invention belongs to the biology project pharmacy filed, which provides a Staphylokinase (SAK) with low pyrogen and it's preparing method. The Staphylokinase has low pyrogen, high purify and strong activity, which is completely fit for the medicinal demand. This invention includes the following steps: a breaking up the material containing with the Staphylokinase and distilling the floating liquid; b. sieving the product from step a with the DEAD gelatin rob, then removing salt and condensing; c. sieving the product form step b with CM gelatin rob, collecting the sample apex, condensing the washing liquid and transforming the medium; d. sieving the product from step c with the Q gelatin rob to obtain the Staphylokinase. The Staphylokinase of this invention has good bolt dissolving effect, and it is safe and efficient for users..

The invention provides a fermenting production method of low-temperature douche fibrinolytic enzyme by marine microorganisms. The method comprises the following steps: directionally domesticating marine microorganisms which produce douche fibrinolytic enzyme to lead the douche fibrinolytic enzyme to grow excellently in a culturing condition; culturing the directionally domesticated douche fibrinolytic enzyme producing strain at a temperature between 10 and 16 DEG C for 24 to 36 hours, and gradually propagating in an inoculum size between 5 to 8 percent; inoculating into a liquid ferment culture medium in an inoculum size of 3 to 9 percent of the volume of a fermentation broth, and culturing for 60 to 96 hours at a temperature between 10 and 16 DEG C to complete fermenting production of the douche fibrinolytic enzyme by the marine microorganisms; centrifuging the fermenting broth in 4000 to 8000rpm to collect liquid which is a crude enzyme; and further concentrating, separating and purifying the crude enzyme according to different requirements and different use objects to prepare the enzyme preparations with different activities, purities and preparation forms.

The application belongs to the technical field of biology, and particularly relates to a preparation method of urokinase. The urokinase expressed by the method is high in output and easy to purify; the expressed urokinase proteins glycosylation is similar with the urokinase expressed by human body, and functions are the same. Moreover, the method is free from the limit of natural resources, and there is no limit to produce the urokinase with the same structure as the human body according to market demand; the method is less in investment, high in output, good in thrombolysis effect, and free from toxic side effects.

The invention provides a reteplase mutant and application thereof. The mutant comprises brand-new mutation sites of two amino acids in a self-shearing ring region, and substitution, deletion or addition of at least one of amino acid residues including alanine and proline is included. The mutant is named as reteplase mutant. The mutant has the abilities of remarkably resisting inhibition of an endogenous inhibitor (PAI-1) of the mutant and enhancing plasminogen activation, can be used as a thrombotic disease medicine and is used for treating various diseases including acute myocardial infarction, acute pulmonary embolism, cerebral apoplexy and venous thrombosis.

The invention provides agrocybe cylindracea plasmin and a preparation method thereof, and relates to the technical field of bioengineering. The agrocybe cylindracea plasmin is composed of a subunit Aand a subunit B, and the molecular weight of the subunit A is 31.4 kDa; the molecular weight of the subunit B is 21.2 kDa; the twelve amino acid sequences of the N-terminus of the subunit A are as shown in SEQ ID No.1; and the twelve amino acid sequences of the N-terminus of the subunit B are as shown in SEQ ID No. 2. The optimum temperature of the plasmin is 47 DEG C; the activity can be preserved at physiological pH of a human body, and different concentration of Fe<2+> have obvious inhibitory effects on the agrocybe cylindracea plasmin; and thrombolytic performance is good, safety is good in use, and production cost is low. A certain research basis for application in the preparation of thrombolytic drugs and / or functional foods is provided, and a new way for the comprehensive utilization of agrocybe cylindracea is further provided.

The invention discloses fusion protein of cytoglobin and sipunculus nudus plasmin, and further provides a preparation method for the fusion protein and related bacterial strain construction. The method comprises the following steps that bacterial strain culture and amplification are carried out, supernatant is separated, sulfuric acid precipitating is carried out, Sephadex G-25 desalting is carried out, and DEAE step-by-step elution and purification are carried out so as to obtain the fusion protein. According to the fusion protein, the optimum pH range is within 5.0-9.0 at 40 DEG C or below,the enzyme activity keeps relatively stable, and the influence of PMSF and Cu<2+> on the activity of fusion protease is relatively large. The fusion protein has the characteristic of targeted degradation of fibrinogen, and the degradation sequence is firstly an alpha chain, secondly a beta chain and finally a gamma chain. The fusion protein has a better thrombolytic effect on urokinase in a thrombus experiment.

The invention provides a tea tree mushroom fibrinolytic enzyme and a preparation method thereof, and relates to the technical field of bioengineering. The tea tree mushroom fibrinolytic enzyme is composed of two subunits A and B, and the molecular weight of the subunit A is 31.4kDa; the subunit The molecular weight of B is 21.2kDa; the twelve amino acid sequence of the N-terminal of subunit A is shown in SEQ ID No.1; the twelve amino acid sequence of the N-terminal of subunit B is shown in SEQ ID No.2. The optimal action temperature of plasmin provided by the invention is 47°C; it can preserve better activity at the physiological pH of human body, and different concentrations of Fe 2+ It has obvious inhibitory effect on tea tree mushroom fibrinolytic enzyme; it has good thrombolytic performance, good safety in use, and low production cost, which provides a certain research basis for the application in the preparation of thrombolytic drugs and / or functional foods , also provides a new way for the comprehensive utilization of tea tree mushroom.

This invention refers to gene engineering technological fields, especially refers to five steps poisonous snake for dissolution of fibrin (original) No. 4 gene, gene contained carrier, parasitifer cells for using the carrier to do gene engineering and using the gene to prepare pharmaceutical of dissolution fibrin against embolic disease formed and caused by thrombus. It separates fibrinolysis factor FII from five steps poisonous snake, sieves and clones fibrinolysis factor FII , expresses fibrinolysis factor FII in yeast cells; purifies expressed results and determines fibrinolysis activity. The fibrinolysis factor is expreed by gene engineering yeast system with high activity and yield, stable quality, and low cost. It is effective dissolved embolism drug, and has great economic benefit and social benefit.

The invention discloses a selenium-rich natto product, which comprises the following components in parts by weight: 35-50 parts of selenium-rich natto powder, 10-16 parts of phytosterol powder and 10-15 parts of green tea extract powder. The selenium-rich natto powder contains selenium natto kinase with high activity and long lasting time, and organic selenium, thus having an excellent antioxidation effect; phytosterol contained in the phytosterol powder has the effects of inhibiting cholesterol absorption of a human body, promoting katabolism of cholesterol, inhibiting biochemical synthesis of the cholesterol and the like; and catechinic acid contained in the green tea extract powder has the effects of inhibiting blood pressure and blood sugar, reducing cholesterol and low density lipoprotein in blood and increasing the content of high density lipoprotein. According to the selenium-rich natto product, the selenium-rich natto powder, the phytosterol powder and the green tea extract powder are combined in scientific proportion to take effect together in three aspects of inhibiting thrombus formation, improving thrombus dissolution and enhancing the toughness of blood vessels, and therefore, the selenium-rich natto product is capable of effectively preventing cardiovascular and cerebrovascular diseases.

The present invention discloses a natto bio-acid preparation. The present invention takes natto powder, which the content of natto kinase is over 1000FU / g, as principal component, also contains biotechnological fulvic acid original powder, and the weight ratio of the two powders is 50-90:50-10. The present invention is capsule, granule, tablet, buccal tablet or other agents type that made by evenly mixing the natto powder and the original powder. After taking the preparation, the bacillus natto is free from the gastric acid and can directly get to intestines. The bacillus natto has the functions of BFA analgesia, anti-inflammatory, protection and repair mucous membrane, and at the same time the dipicolinic acid in the natto bacillus can effectively exterminate and restrain harmful germs and viruses in intestinal, further make the intestinal and stomach health. While BFA improves human microcirculation, and promotes blood circulation, BFA brings the thrombolytic effect of natto kinase into better play, which the ideal effect of both activating blood and thrombolysis, activating blood promoting thrombolysis is achieved, which makes the present invention, the combination with lower single amount of each component, achieves the effect of better than the effect of single use of each component, and with the method makes the present invention have stronger comprehensive and lower cost.

The invention relates to a method for producing a nattokinase liposome from phytosterol. The method for producing a nattokinase liposome from phytosterol is characterized by comprising: (1) a step of raw material selection, in which lecithin, phytosterol, ether, a buffer solution and a solution of nattokinase are selected in mass ratio of 100-300 mg:90-200 mg:2-5 mL:5-10 mL:5-10 mL for later use;2) a step of blank liposome preparation, in which the lecithin, the phytosterol and the ether are mixed, the mixture is subjected to rotary evaporation to be formed into a uniform lipoid membrane to cover the internal bottom of a pear-shaped flask, the buffer solution is added into the flask, glass beads are added into the flask, the flask is rotated and shaken at 60 DEG C for 30 to 90 minutes, the mixture in the flask is treated by ultrasonic wave in a water bath for 10 to 20 minutes, and the materials in the flask is subjected to freeze drying to form a precursor substance of the liposome; and 3) a step of hydration, in which the solution of nattokinase is added into the precursor substance of the liposome for hydration in nitrogen flow for 10 to 20 minutes and thus the nattokinase liposome is obtained. The method is simple in process and can reduce the influences of cholesterol on human body.

The invention relates to the field of medicine and discloses a urokinase supported microbubble used for treating PTE (pulmonary thromboembolism) and adopting a D-dimer monoclonal antibody as a targetdevice. The microbubble is of phospholipid texture, a thrombolytic drug is supported on the microbubble, and the D-dimer monoclonal antibody is attached to the surface of the microbubble. The drug supported microbubble can be specifically bonded with a D-dimer on a thrombus through the D-dimer monoclonal antibody, so that the drug supported microbubble is bonded with the thrombus, then the in-vivodrug supported microbubble breaks under the action of inertial cavitation produced by in-vitro ultrasonic irradiation, and fixed-point release of the thrombolytic drug is realized. The drug is limited at the thrombus part, wounds are avoided, the bleeding risk is low, the microbubble is small in drug dose and good in thrombolytic effect, and the operation is controllable.

The present invention relates to one kind of and its culturing and preparing process. The plasmin is prepared with N. sitophila strain No. 17 in the preservation number of CGMCC No. 1836, and throughfermentation, separation and purification. It consists of two subunits of molecular weight 30000 and 15500 separately and isoelectric point of 7.9+ / -0.2. The plasmin has high thrombolysis performance,no bleeding activity, no blood coagulating activity and no obvious acute toxicity, and thus possesses clinical test, development and application foreground. The plasmin of the present invention is one kind of extracellular enzyme, and is favorable to post separation and purification. Its preparation adopts wheat bran and soybean residue as main culture medium material, and thus has low material cost.

The invention relates to the technical field of medical apparatuses. The invention discloses a built-in medical ultrasonic thrombolytic therapy apparatus, which comprises an infusion device, an ultrasonic loading module and an ultrasonic indwelling wave-guide tube. A front cover plate and an amplitude-change pole of an ultrasonic transducer in the ultrasonic loading module are made from a TC4 titanium alloy material, and through holes, which are [phi]1mm in diameter, are kept in the middles of the front cover plate and the amplitude-change pole. The ultrasonic indwelling wave-guide tube entersinto a blood vessel from the upstream side of the blood vessel that thrombus occurs along the direction of a blood flow. A plurality of small holes are excavated in two sides of the part, which enters the blood vessel, of the ultrasonic indwelling wave-guide tube, so that ultrasonic wave is directly emitted into the blood vessel having the thrombus, and then under the assistance of thrombolytic agent, the thrombus can be ablated. Based upon experimental verification, the therapy apparatus, on treating thrombotic diseases, is non-invasive, simple and convenient to operate and suitable for reuse. Ultrasonic energy merely plays a local role in vivo, and an ultrasonic action and medicines directly reach focuses, so that a good thrombolysis effect is achieved; and meanwhile, the therapy apparatus has the huge advantages of being low in injury on surrounding tissues, safe and free from side effects and adverse reactions, and the like.

The invention relates to a Qilong soft capsule and a preparation method. Doctors of traditional Chinese medicine believe that the symptoms of stroke, such as hemiplegia, are often caused due to insufficiency of middle-warmer energy and invasion by pathogens, liver blood stasis and meridian and collateral obstruction as well as qi deficiency and blood stasis. Hemiplegia induced by stroke is suitable to be treated by tonifying qi and activating blood. The Qilong capsule has good protective effects on cerebral injury, has the effect of improving cerebral microcirculation and has antithrombotic and thrombolytic effects. The Qilong soft capsule comprises a capsule shell, wherein the capsule shell contains content. The Qilong soft capsule is characterized in that the content comprises 350-420 parts of radix astragali, 360-450 parts of earthworm, 15-30 parts of Danshen root, 15-28 parts of Chinese angelica, 15-30 parts of red paeony root, 15-30 parts of Szechuan lovage rhizome, 8-15 parts of safflower and 1-5 parts of peach seed by weight; the capsule shell comprises 170-210 parts of gelatin and 200-230 parts of purified water by weight.

The invention discloses a preparation method of natural Sipunculus fibrinolysin and application thereof. The natural Sipunculus fibrinolysin has a partial amino acid sequence of SEQ ID NO: 1. The natural Sipunculus fibrinolysin has a very good antithrombotic curative effect.

The invention provides a fibrinolytic enzyme, characterized in that, the amino acid sequence of the fibrinolytic enzyme is SEQ ID NO.1, and the nucleotide coding sequence of the fibrinolytic enzyme is SEQ ID NO. 2. The preparation method of the fibrinolytic enzyme provided by the present invention is simple, the obtained enzyme activity is high, the thrombolytic rate in vitro can reach more than 80%, and the thrombolytic ability in vivo is also higher than that of commonly used drugs urokinase and streptokinase, and it also has a good in vitro Anticoagulant effect, has a good clinical application prospect.

This invention belongs to the biology project pharmacy filed, which provides a Staphylokinase (SAK) with low pyrogen and it's preparing method. The Staphylokinase has low pyrogen, high purify and strong activity, which is completely fit for the medicinal demand. This invention includes the following steps: a breaking up the material containing with the Staphylokinase and distilling the floating liquid; b. sieving the product from step a with the DEAD gelatin rob, then removing salt and condensing; c. sieving the product form step b with CM gelatin rob, collecting the sample apex, condensing the washing liquid and transforming the medium; d. sieving the product from step c with the Q gelatin rob to obtain the Staphylokinase. The Staphylokinase of this invention has good bolt dissolving effect, and it is safe and efficient for users..

The present invention discloses a rosa roxburghii composition for anticoagulation and a preparation method thereof. The composition is prepared from the following components in parts by weight: 10-90 parts of roxburgh rose concentrated solution, 2-10 parts of rhizoma polygonati, 2-10 parts of radix puerariae, 2-10 parts of rhizoma dioscoreae, 2-10 parts of poria cocos, 2-10 parts of radix ginseng, 1-5 parts of earthworm peptide, 1-5 parts of Y-aminobutyric acid, 1-5 parts of xylitol, 1-5 parts of cordyceps militaris, 1-5 parts of mulberry and the balance of purified water. According to the rosa roxburghii beverage for anticoagulation prepared by the preparation method disclosed by the invention, the roxburgh rose concentrated solution has a good anticoagulant effect and can be used for making up the defects of heparin medicines; and meanwhile, the medicine can directly penetrate through gastric digestive juice to enter small intestines, the high anticoagulation effect is achieved, and the good thrombus dissolving effect is achieved.

The invention relates to the technical field of genetic engineering, in particular to the No. 2 gene of Agkistrodon akistrodon (pentapod venom) dissolving fibrin (original), a carrier containing the gene, a host cell genetically engineered by using the carrier and the The gene is used to prepare medicines for dissolving fibrin (ogen) to resist embolism diseases caused by thrombus formation. Isolate the fibrinolytic factor FII from the crude venom of the five-step snake; complete the screening and cloning of the fibrinolytic factor FII gene; express the fibrinolytic factor FII in yeast cells; purify the expressed product and measure the fibrinolytic activity. The cellolytic factor expressed by the genetically engineered yeast system in the present invention has high activity, large output, stable quality and low cost, and can be a new type of powerful thrombolytic drug with huge social and economic benefits.

A snake soluble fibrous protein No.8 gene, carrier containing the gene, hosting cell for gene engineering by the carrier and medicine for preparing soluble fibrous protein by the gene are disclosed. It is prepared by separating fibrous soluble factor FII from snake venoms, screening and cloning fibrous soluble factor FIIgene, expressing fibrous soluble factor FIIin yeast cell, purifying and measuring fibrous soluble activity of expressing product. Its advantages include low cost, high activity and output.